Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 1, 2007, Pages 87-93

  Wirth, M ^a   Tyrrell, C ^b   Delaere, K ^c   Sanchez Chapado M ^d   Ramon, J ^e   Wallace, D M A ^f   Hetherington, J ^g   Pina, F ^h   Heyns, C F ⁱ   Navani, S ^j   Armstrong, J ^j  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c Sittard Geleen Heerlen   (Netherlands)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^e SHEBA MEDICAL CENTER   (Israel)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g PRINCESS ROYAL HOSPITAL   (United Kingdom)

^h HOSPITAL DE SÃO JOÃO   (Portugal)

ⁱ UNIVERSITY OF STELLENBOSCH   (South Africa)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BACKACHE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FOLLOW UP; GYNECOMASTIA; HEMATURIA; HERNIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IMPOTENCE; LIBIDO; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MASTALGIA; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PAIN; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; NITRILES; PLACEBOS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 33847609549     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500916     Document Type: Article

References (20)

1. Smith Jr JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54 (Suppl 6A): 8-14.
2. Pitceathly C, Maguire P. The psychological impact of cancer on patients' partners and other key relatives: A review. Eur J Cancer 2003; 39: 1517-1524.
3. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lameratp L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: Findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250-2254.
4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-108.
5. Pilepich MV, Winter K, Lawton CA, Krish RE, Wolkov HB, Movsas B et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol phys 2005; 61: 1285-1290.
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
7. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396, 1480.
8. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582.
9. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-2276.
10. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173-181.
11. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-461.
12. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, on behalf of the 'Casodex' Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 2006; 97: 247-254.
13. Aus G, Abbou CC, Bolla M, Heidenreich A, Van Poppel H, Schmid H-P et al. European Association of Urology Guidelines on Prostate Cancer. Available at: http://www.uroweb.nl/files/uploaded_files/ 2005Prostate%20Cancer.pdf. Accessed December 19, 2005.
14. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.
15. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J et al. Bicalutamide (Casodex) 150mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146-151.
16. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 2005; 8: 194-200.
17. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D et al., on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002; 168: 429-435.
18. Wirth MP, See WA, McLeod D, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865-1870.
19. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer program: Demography. Urol Oncol 2001; 6: 43-47.
20. Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P et al., on behalf of the Scandinavian Prostate Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: Updated results from the Scandinavian Prostate Cancer Group (SPCG) Study 6 at 7.1-years' median follow-up. Scand J Urol Nephrol 2006 (in press).